Roots Mental Health Treatment Center
- Transcranial Magnetic Stimulation (TMS)
- Ketamine Therapy
- Psychedelic Therapy
Long Beach, CA
Psychedelic Therapy clinics in Long Beach
Psychedelic-assisted therapy in Long Beach sits mostly in the ketamine-assisted psychotherapy category, with some clinics also preparing for state-specific psilocybin frameworks. Psychiatric referrals for complex cases route through Long Beach Memorial, MemorialCare, and MillerChildren's. Demand reflects a port-industry and diverse coastal population.
Ketamine-assisted psychotherapy has the strongest US evidence base among psychedelic modalities. Psilocybin is not FDA approved and is only legally accessible within research or specific state programs. MDMA therapy is investigational. Clinics in Long Beach, California should be evaluated for therapist training, safety protocols, and honest evidence framing. California Medical Board and strict medspa medical director rules determines what can legally be offered.
With psychedelic therapy clinics on Regenerated.com in Long Beach, patients can compare clinician training, integration support, and legal framework before booking.
MD on staff
Psychedelics Transdiagnostic Therapeutics
- NAD IV Therapy
- Vitamin IV Therapy
- IV Therapy
- IV Hydration
- Ketamine Therapy
MD on staff
Roots Mental Health Treatment Center
- IV Therapy
- Transcranial Magnetic Stimulation (TMS)
- Neurofeedback Therapy
- Ketamine Therapy
- Psychedelic Therapy
Regulatory context
A note on California's psychedelic therapy rules.
Ketamine is a DEA Schedule III controlled substance, FDA-approved as a dissociative anesthetic and used off-label for treatment-resistant depression, PTSD, and chronic pain. The FDA approved esketamine (Spravato) in 2019 for treatment-resistant depression under a Risk Evaluation and Mitigation Strategy (REMS) program that requires in-office administration at certified sites. MDMA-assisted therapy remains Schedule I; the FDA issued a Complete Response Letter in August 2024 to Lykos Therapeutics on its MDMA new drug application. Psilocybin is Schedule I and holds FDA Breakthrough Therapy designation through sponsors such as Compass Pathways and Usona, but has not received FDA approval. Oregon Measure 109 (passed 2020, operational 2023) created a state psilocybin service center framework, and Colorado Proposition 122 (2022) authorized regulated healing centers.
-
SB 803 (2023, vetoed) and SB 1012 (2024, stalled)
Proposed regulated therapeutic access to psilocybin, MDMA, mescaline, and DMT; Governor Newsom vetoed SB 58 (2023) citing lack of treatment guidelines. -
Local decriminalization resolutions
Oakland (2019), Santa Cruz (2020), Arcata, San Francisco, and Berkeley have passed non-binding resolutions deprioritizing enforcement of natural psychedelics; no legal therapeutic framework.
California enforces federal DEA scheduling. The Medical Board of California investigates prescriber misconduct, including ketamine diversion and inadequate patient monitoring. Several high-profile California ketamine-related deaths (including Matthew Perry's 2023 overdose) have intensified board scrutiny of clinic practices. DEA enforcement targets compounding, diversion, and Ryan Haight Act telehealth compliance.